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Milan criteria are the most frequently used limits for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC),
but our previous experience with expanded criteria showed encouraging results. The aim of this study was to investigate
whether our expanded Clinica Universitaria de Navarra (CUN) criteria (1 nodule up to 6 cm or 2-3 nodules up to 5 cm each)
could be used to select patients with HCC for LT. Eighty-five patients with HCC fulfilling CUN criteria were included as
candidates for LT. Survival of transplanted HCC patients was compared with survival of patients without HCC (n  180). After
the exclusion of 2 patients with tumor seeding of the chest wall due to pre-LT tumor biopsy, survival and recurrence rates were
compared according to tumor staging. Twenty-six out of 85 (30%) patients exceeded Milan criteria. Twelve patients had tumor
progression on the waiting list. Patients exceeding Milan criteria had a higher dropout rate due to tumoral progression. One-,
3-, 5-, 7-, and 10-year survival rates of the 73 transplanted HCC patients were 86%, 74%, 70%, 61%, and 50%, respectively.
Survival of patients with HCC was significantly lower than that of patients without HCC, but by multivariate analysis, HCC was
not associated with lower survival. Tumor recurrence and survival rates were similar for patients fulfilling Milan and CUN
criteria. Pathological staging showed 55 patients within Milan criteria, 7 patients exceeding them but within CUN criteria, and
9 patients exceeding CUN criteria. Tumor recurrence rates were 2/55 (4%), 0/7 (0%), and 4/9 (44%) in each of these groups,
respectively. In conclusion, following CUN criteria could increase the number of HCC patients who could benefit from LT,
without worsening the results. Because of the short number of patients in this series, these data need external validation. Liver
Transpl 14:272-278, 2008. © 2008 AASLD.
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Liver transplantation (LT) is the best treatment option for
patients with hepatocellular carcinoma (HCC) and liver
cirrhosis, unless they have excellent liver function and
minimal portal hypertension.1 Early experience of LT for
patients with HCC was poor because tumoral recurrence
was very frequent.2 In 1996, Mazzaferro et al.3 reported
encouraging results in patients with a single tumor of up
to 5 cm in diameter or 2-3 lesions of up to 3 cm. These
Milan criteria were adopted by the United Network for
Organ Sharing and by most transplant centers as selec-
tion guidelines for LT in patients with HCC.
However, recent data suggest that Milan criteria may
be too conservative. Yao et al.4 reported their results
with a moderate expansion of these criteria [the so-
called University of California at San Francisco (UCSF)
criteria]. Patients selected with these expanded criteria
had disease-free survival that was comparable to sur-
vival of patients selected with Milan criteria.
We published the results of our own series of LT for
patients with HCC in 2001.5 Our selection criteria for
LT were 1 nodule of up to 6 cm in diameter or 2-3
nodules of up to 5 cm. Tumor recurrence rates were
comparable to those obtained by other groups that
used the stricter Milan criteria.
Abbreviations: CI, confidence interval; CT, computed tomography; CUN, Clinica Universitaria de Navarra; HCC, hepatocellular
carcinoma; HR, hazard ratio; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; MR, magnetic resonance; NS, not
significant; UCSF, University of California at San Francisco.
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In this article, we update the results of our series of
LT for HCC using our expanded criteria. We have also
analyzed the possible impact on survival and tumor
recurrence rates of these criteria in comparison with
Milan criteria according to preoperative staging.
PATIENTS AND METHODS
Criteria for LT and Preoperative Follow-Up
Patients with unresectable HCC were considered poten-
tial candidates for LT if they fulfilled the Clinica Univer-
sitaria de Navarra (CUN) criteria (1 tumoral nodule not
larger than 6 cm in diameter or 2-3 nodules of up to 5
cm each). Both dynamic computed tomography (CT)
and magnetic resonance (MR) scans were obtained for
each patient, and the largest tumor size on either study
was used for indicating LT. Macroscopic vascular inva-
sion and extrahepatic spread were excluded with tho-
racic and abdominal CT, cerebral MR, and bone scin-
tigraphy. After inclusion in the waiting list, treatment of
HCC (usually transarterial chemoembolization) was
used or not according to the criteria of the patient’s
physician (based on the expected waiting time for LT
and the hepatic function of the patient). Hepatic CT/MR
imaging scan was repeated at least every 3 months
while the patient was on the waiting list. Patients were
excluded from the waiting list if at any time staging
exceeded the aforementioned criteria because of tumor
progression.
Patients
All patients with HCC on the waiting list for LT between
1991 and 2005 were included (8 patients with inciden-
tal tumors transplanted in that period of time were not
included in the study). Pathological records of the spec-
imens of the explant were reviewed. In order to detect
HCC recurrence, alpha-fetoprotein, chest X-ray film,
and abdominal ultrasound were repeated every 6
months after transplantation or when clinically indi-
cated in order to detect HCC recurrence. Causes of
death of deceased patients were recorded.
Statistical Analyses
Tumor progression exceeding CUN criteria was studied in
all the patients who were initially considered for LT. The
risk of progression of patients who fulfilled Milan criteria
when theywere included on thewaiting list was compared
with the risk of those who exceeded these criteria.
Survival of patients transplanted for HCC who fulfilled
CUN criteria was compared with survival of all the pa-
tients transplanted for liver cirrhosis without HCC be-
tween 1991 and 2005. The potential influence of donor
and recipient age and sex, Child-Pugh status at trans-
plantation, HCC, and etiology of liver cirrhosis (hepatitis C
virus versus other causes of cirrhosis) on survival was
studied. Variables with P  0.2 in the univariate analysis
were included in a multivariate analysis of survival.
To compare Milan and expanded criteria, we excluded
2 patients who had HCC recurrence due to tumor seed-
ing caused by pre-LT tumor biopsy. Actuarial rates of
survival and tumor recurrence were compared accord-
ing to radiological maximum staging. Intention-to-treat
actuarial rates of survival were compared according to
radiological staging at listing.
Statistical Methods
Categorical variables are expressed as absolute number
(%). Continuous variables are expressed as median (in-
terquartile range). Comparison of groups was done by
the chi-square method (categorical variables) or Mann-
Whitney U test (continuous variables).
Actuarial rates of survival and tumor recurrence and
their 95% confidence intervals were obtained with the
Kaplan-Meier method. Comparisons between curves
were done with the long-rank test (categorical variables)
and univariate Cox regression model (continuous vari-
ables). Multivariate analysis of survival was done with
the multivariate Cox model.
Differences were considered significant if P values
were below 0.05.
RESULTS
Between 1991 and 2005, 85 patients fulfilling our cri-
teria were included on the waiting list for LT. Twelve
patients exceeded these criteria during regular restag-
ing while on the waiting list (Fig. 1). The remaining 73
patients transplanted for HCC were compared with 178
patients transplanted for cirrhosis without HCC. Fi-
nally, the comparison between the CUN criteria and the
Milan criteria in terms of survival and tumor recurrence
after LT was studied after the exclusion of 2 patients
who had tumor recurrence due to cutaneous seeding by
pre-LT tumor biopsy.
Analysis of Progression
Of the 85 patients included on the LT waiting list for
HCC, 59 fulfilled the Milan criteria, and 26 (30%) did
85 patients fulfilling radiological criteria
Study of tumor progression on the waiting list.
Intention to treat analysis of survival (Milan vs.
expanded criteria)
Progression above expanded criteria: 12
73 patients transplanted
Comparison of survival vs. patients without HCC
Tumor seeding by pre-transplant tumor biopsy: 2
71 patients
Comparison of Milan and expanded criteria on
predicting outcome
Figure 1. Evolution of patients considered for liver trans-
plantation for hepatocellular carcinoma (HCC).
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not. Dropout from the waiting list due to tumor progres-
sion occurred in 4 patients (7%) within the Milan crite-
ria and in 8 patients (30%) exceeding them at the time
of inclusion on the list. The actuarial risk of progression
was significantly higher for patients who exceeded the
Milan criteria at diagnosis (Fig. 2). The risk of progres-
sion was not significantly lower among patients receiv-
ing antitumoral therapy while on the list. Currently, 6
of these patients are alive (5 of them after transplanta-
tion according to expanded criteria).
Comparison of Patients With HCC Versus
Patients Without HCC
General characteristics of both groups of patients are
given in Table 1. Patients with HCC had a significantly
higher frequency of hepatitis C virus infection, were sig-
nificantly older, and had less severe liver cirrhosis as
assessed by the Child-Pugh status or the Model for End-
Stage Liver Disease score. One-, 3-, 5-, 7-, and 10-year
actuarial (95% confidence interval) survival rates were
86% (78%-94%), 74% (68%-84%), 70% (59%-81%), 61%
(48%-74%), and 50% (35%-65%), respectively, for pa-
tients with HCC and 91% (87%-99%), 88% (83%-93%),
84% (78%-90%), 80% (74%-87%), and 76% (68%-83%),
respectively, for patients without HCC. The difference in
actuarial survival between both groups was statistically
significant (P  0.002; Fig. 3). Other variables associated
with lower survival were hepatitis C virus infection, donor
age (above 60 years), and higher recipient age (Table 2). By
multivariate analysis, only higher recipient age was inde-
pendently associated with a lower survival. The associa-
tion between survival and HCC was close to statistical
significance but did not reach it. Causes of death in both
groups are detailed in Table 3.
For Peer ReviewWithin Milan criteria (N=59)
Above Milan 
criteria (N=26)
P<0.0001
Months
Patients at risk
Within Milan 59 33 15 3
Above Milan 26 5 0 0
Figure 2. Tumoral progression
while patients were on the wait-
ing list for transplantation ac-
cording to whether or not the pa-
tients fulfilled Milan criteria.
TABLE 1. Comparison of Liver Transplant Recipients With or Without Hepatocellular Carcinoma
Hepatocellular Carcinoma
(n  73)
No Hepatocellular Carcinoma
(n  178) P
Hepatitis C 40(55%) 47(26%) 0.001
Female sex 13(18%) 48(27%) NS
Female donor sex 28(39%) 70(40%) NS
Child status 0.001
A 26(36%) 7(4%)
B 32 (44%) 92 (52%)
C 15 (20%) 79 (44%)
MELD at listing 13 (10-16) 16 (14-20) 0.001
MELD at transplant 12 (10-16) 16 (14-21) 0.001
Age (years) 60.8 (54.9-67.4) 55.05 (47.5-62.0) 0.001
Donor age (years) 47 (26-64) 44 (25-59) NS
Abbreviations: MELD, Model for End-Stage Liver Disease; NS, not significant.
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Impact of the Expanded Criteria
Of the 73 patients transplanted, 47 patients were
within Milan criteria, and 26 (35%) exceeded them. Two
patients exceeding Milan criteria were excluded from
this analysis because they had HCC recurrence due to
tumor seeding by pre-LT tumor biopsy. Tumor recurred
in 4 patients (8%) fulfilling the Milan criteria and in 2
patients exceeding them (8%). Tumor recurrence and
survival were not significantly different between these 2
groups. One-, 3-, 5-, 7-, and 10-year actuarial survival
rates (95% confidence interval) were 83% (72%-94%),
73% (60%-85%), 70% (56%-84%), 70% (56%-84%), and
43% (17%-69%), respectively, for patients fulfilling the
Milan criteria and 92% (82%-100%), 78% (61%-95%),
73% (55%-92%), 56% (35%-76%), and 56% (35%-76%),
respectively, for patients exceeding them (Fig. 4).
Intention-to-treat survival of the 26 patients who ex-
ceeded the Milan criteria when they were included on
the waiting list was compared with survival of those
who fulfilled Milan criteria (n 59). One-, 3-, 5-, 7-, and
10-year actuarial survival rates (95% confidence inter-
val) were 88% (80%-96%), 73% (61%-85%), 66% (53%-
79%), 66% (53%-79%), and 49% (30%-69%), respec-
tively, for patients fulfilling the Milan criteria and 88%
(76%-100%), 72% (55%-90%), 68% (49%-86%), 52%
(31%-73%), and 52% (31%-73%), respectively, for pa-
For Peer Review
Cirrhosis and HCC (N=73)
Cirrhosis without HCC (N=178)
P=0.002
Months
Patients at risk
No HCC            178 157 141 130  121 109 93   80  70    60   48  41   36    27   16   8     2     0
HCC                   73   61   52   44    40   34  34   32  23 17   13  12    9      6      4    2     2     0
Figure 3. Survival after liver
transplantation of patients with
liver cirrhosis with or without
hepatocellular carcinoma (HCC).
TABLE 2. Variables With Influence on Survival in 251 Patients Transplanted With Liver Cirrhosis (73 Patients With
Hepatocellular Carcinoma and 178 Without Tumor)
Univariate Analysis Multivariate Analysis
HR (95% CI) P HR (95% CI) P
Age (years) 1.064 (1.033-1.095) 0.001 1.051 (1.019-1.084) 0.002
Donor  60 years 1.913 (1.096-3.339) 0.022 1.559 (0.887-2.739) 0.122
Hepatitis C 1.620 (1.000-2.623) 0.05 1.236 (0.744-2.053) 0.413
Hepatocellular carcinoma 2.097 (1.287-3.419) 0.003 1.589 (0.942-2.679) 0.082
Abbreviations: CI, confidence interval; HR, hazard ratio.
TABLE 3. Causes of Death of Patients Transplanted
for Liver Cirrhosis With or Without Hepatocellular
Carcinoma
Hepatocellular
Carcinoma
[28/73 (38%)]
Cirrhosis
Without
Tumor
[39/178
(22%)]
Infection 5 (18%) 7 (18%)
De novo neoplasia 6 (21%) 17 (44%)
Recurrent hepatocellular
carcinoma 8 (29%) 0
Recurrent viral hepatitis 4 (14%) 1 (2%)
Other complications 5 (18%) 14 (36%)
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tients exceeding them (Fig. 5). Differences between both
groups were not significant.
Pathological staging after LT disclosed that 55 pa-
tients (77%) were within Milan criteria, 7 patients
(10%) exceeded them but fulfilled the expanded cri-
teria, and 9 patients (13%) exceeded the latter. Tumor
recurrences were diagnosed in 2/55 (4%), 0/7 (0%),
and 4/9 (44%) in each of these groups, respectively.
Tumor recurrence rates were significantly higher in
patients who exceeded CUN criteria than in the other
2 groups (Fig. 6).
Vascular invasion, the single factor most frequently
associated with tumor recurrence, was also associated
with a higher rate of recurrence in this series. Recur-
rence was diagnosed in 3/11 (27%) patients with vas-
cular invasion and 3/60 (5%) patients without vascular
invasion. Our criteria and the Milan criteria (radiologi-
cal or pathological) were not associated with a different
rate of vascular invasion.
DISCUSSION
The most relevant finding of this article is the confirma-
tion that the Milan criteria could be expanded without
For Peer Review
Within Milan criteria (N=47)
Above Milan criteria (N=24)
P=0.5
Months
Patients at risk
Within Milan      47   37  30   27   24   20   18   11    7     5     3     3    2    1    1     1      0     0
Above Milan      24   21  20   16   14   13   13    9     9     8     7     5   2    2    1     0      0     0
Figure 4. Survival after liver
transplantation of patients
transplanted according to ex-
panded criteria comparing pa-
tients that fulfilled and exceeded
Milan criteria.
For Peer Review
Within Milan criteria (N=59)
Above Milan criteria (N=26)
P=0.82
Months
Patients at risk
Within Milan      59   52  43   35  29  25  22  20   12   10   7   4    4   1    1     1    0    0
Above Milan      26   23  21   17  14  13  13  10    8     7    6   5    4    2 1     0    0    0
Figure 5. Survival of patients
with hepatocellular carcinoma
who were listed for liver trans-
plantation comparing patients
that fulfilled and exceeded Milan
criteria at listing.
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worsening the results of LT in patients with HCC, as
suggested by other groups.4 With the Milan criteria as
the limit for LT, 26/73 (35%) patients would not have
been transplanted, and this would have precluded their
access to the only potentially curative option for them.
Because these patients had survival and recurrence
rates comparable to those of patients fulfilling the Milan
criteria, there seems to be no objective reason for deny-
ing LT to these patients.
Mazzaferro et al.3 found that patients with patholog-
ical tumoral staging exceeding the Milan criteria had a
higher recurrence rate than patients fulfilling them.
Yao et al.6 had similar findings: patients fulfilling their
UCSF criteria had better prognosis than patients with
higher tumoral burden. Similarly, we have found that
patients exceeding our criteria at the examination of the
pathological specimen had higher recurrence rates and
lower survival rates. Recently, in a large multicenter
series, Onaca et al.7 found that patients fulfilling Milan
criteria at the examination of the liver explant have
survival similar to that of patients with 1 nodule of up to
6 cm or 2-4 nodules smaller than 5 cm. Patients ex-
ceeding these limits have significantly lower survival.
Anyway, the indication or contraindication for LT must
be based on radiological staging, and unfortunately,
radiological staging does not have a good correlation
with the pathological examination.8 In our series, the
discrepancy between radiological and pathological
staging has 2 causes. Radiological techniques occa-
sionally missed tumor nodules. Additionally, radiologi-
cal techniques found some lesions to be larger than in
the pathological specimen; this may be due in part to
the effect of pre-LT treatment.
Establishing a limit for LT among patients with HCC
is the consequence of the scarcity of available grafts.
The parameter most frequently associated with the risk
of recurrence is vascular invasion,5,9-11 but the pres-
ence or absence of microscopic vascular invasion is
difficult to ascertain solely on the basis of the number
and size of tumor nodules. In our series, the risk of
vascular invasion was similar in patients within or
above the Milan criteria, albeit if CUN criteria were
fulfilled. Probably other markers of tumor behavior
such as the grade of histological differentiation could
better reflect the risk of recurrence. Other markers
such as cell-cycle modulators12 or the detection of bone
marrow micrometastases13 are better related to vascu-
lar invasion and could be useful predictive factors of
tumor recurrence, but their clinical role needs to be
evaluated in larger studies.
In conclusion, the Milan criteria, currently used in
most centers as the limit for LT in patients with HCC,
seem to be too restrictive. Patients transplanted ac-
cording to the expanded criteria presented herein (1
nodule not bigger than 60 mm or 2-3 nodules up to 50
mm) have survival and recurrence rates that do not
differ from those fulfilling the Milan criteria. Patients
exceeding Milan criteria have a higher rate of dropout
from the waiting list for transplantation that could
lead to a lower intention-to-treat survival. Future
studies with higher numbers of patients and longer
follow-up need to confirm these results before these
criteria become the standard limits for LT in patients
with HCC.
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For Peer ReviewWithin Milan criteria (N=54)
Above expanded criteria (N=10)
P=0.0025
Months
Expanded criteria(N=7)
Patients at risk
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Figure 6. Tumor recurrence af-
ter liver transplantation of pa-
tients transplanted for hepato-
cellular carcinoma according
to their pathological staging
(within Milan criteria, above Mi-
lan criteria but within expanded
criteria, and above expanded
criteria).
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